Practice News
VCS physicians named Top Doctors List 2012!
Congratulations to our physicians who made the Northern Virginia Magazine and/or Washingtonian Top Doctors List in 2012! Click here to see the entire list of winners.
Don’t be a chicken!
March is Colorectal Cancer Awareness Month. Don't be a chicken, get screened today!
Most people should begin screening at age 50, but if you are at increased risk of developing colorectal cancer, speak with your doctor about finding polyps early, before they turn into cancer.
Did you know that diets high in red or processed meat can increase the risk of developing colorectal cancer? Learn about more risk factors by clicking here.
To schedule an appointment, please call (703) 208-3155
Dr. Robert discusses latest breast cancer treatments on free webinar
On Monday, February 27, 2012 from 12:00p-1:00p, our own Dr. Nicholas Robert will discuss the latest findings from this international scientific symposium that provides up to the minute information on the exciting strides made in the field of breast cancer research and treatment. Watch this free life webinar from the comfort of your home. Click here to register: http://w.on24.com/r.htm?e=399746&s=1&k=EA3AA2244433E4A15646D6212E1F7DA3
Dr. Amy Irwin to lead a Leukemia & Lymphoma Society discussion at Life with Cancer on March 13th
The presentation titled, "Cancer Treatment – How to Make Informed Choices about Standard Care and Clinical Trials" will be held at the Inova Loudoun Hospital on March 13th. This event is open to the public, but pre-registration is required.
To register contact Margo DeLong at 703.399.2959
Inova Loudoun Hospital is located at:
44055 Riverside Parkway
Leesburg, VA 20176
The presentation will be in conference rooms A & B from 6:00-8:00.
Click here for more information.
Dr. Patel featured in Drug Shortage Report
Drug Shortages Force Tough Choices for Patients, Doctors
Our own Dr. Dipti Patel discusses the choices she's had to make for her patients due to drug shortages: http://video.pbs.org/video/2110607095
VCS Receives Recognition for Cancer Care from Prestigious National Oncology Organization
Fairfax, Va. (Mar. 1, 2011)– Virginia Cancer Specialists has become one of the first oncology practices in the nation to be recognized by the Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO). The QOPI® Certification Program is a new initiative to certify oncology practices that meet rigorous standards for high-quality cancer care.
“We have raised the bar for cancer care in northern Virginia,” said Gregory Orloff, president of Virginia Cancer Specialists, “This certification from ASCO and QOPI underscores our commitment to excellence for our patients and we are extremely proud to be among the first to receive this recognition.”
“Having a national certification program that acknowledges the highest standards of cancer care delivery is a major milestone for health care in America,” said Douglas W. Blayney, MD ASCO Immediate Past President. “Not only should this community oncology practice feel tremendous pride in its QOPI certification, but its patients can be confident in the quality of care they are receiving.”
QOPI is a voluntary, self-assessment and improvement program launched by ASCO in 2006 to help hematology-oncology and medical oncology practices assess the quality of the care they provide to patients. Through the QOPI program, practices abstract data from patients’ records up to twice per year and enter this information into a secure database. Virginia Cancer Specialists is one of 59 who has currently received the inaugural certification. More than 650 oncology practices have registered in the QOPI program.
QOPI analyzes individual practice data and compares these to more than 80 evidence-based and consensus quality measures. The information is then provided in reports to participating practices. Individual practices are also able to compare their performance to data from other practices across the country. Based on this feedback, doctors and practices can identify areas for improvement.
The QOPI Certification Program provides a three-year certification for outpatient hematology-oncology practices that meet standards for quality cancer care.
About Virginia Cancer Specialists
For more than 30 years, Virginia Cancer Specialists (VCS) has contributed to the campaign against cancer and diseases of the blood. VCS has nine locations throughout Northern Virginiastaffed by highly-skilled physicians, each promising exceptional care. This care consists of advancements in early detection, treatment, and clinical trials. Offering emotional as well as physical support, VCS is home to the world’s most advanced cancer treatment capabilities. By illustrating the outpatient emphasis of cancer treatment, VCS allows physicians and patients to create an individual plan in a familiar setting.
About ASCO:
The American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With nearly 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. For ASCO information and resources, visitwww.asco.org. Patient-oriented cancer information is available atwww.Cancer.Net.
Media Contact:
Natalie Mellon
Virginia Cancer Specialists
(703) 638-8619
# # #
VCS Chosen to Join Multiple Myeloma Research Consortium
Virginia Cancer Specialists chosen to join theMultiple Myeloma Research Consortium
The cancer center is honored to be one of only 16 MMRC member institution sites across North America dedicated to multiple myeloma research
Fairfax, Va. (Feb. 8, 2011) — Virginia Cancer Specialists (VCS), a 30-physician practice that has contributed to the campaign against cancer and diseases of the blood for more than three decades, is excited to announce that it is now a member institution of the Multiple Myeloma Research Consortium (MMRC).
The MMRC is an early-stage drug development consortium dedicated to promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer. As a member institution, Virginia Cancer Specialists will participate in clinical research activities of the Consortium.To date, the MMRC has advanced 30 early-stage clinical trials. MMRC member institutions also contribute to the MMRC Tissue Bank, which stores bone marrow and peripheral blood samples from multiple myeloma patients and serves as a bridge between laboratory and clinical research.
“Virginia Cancer Specialists already has a long history of committing its expertise and resources to advancing cancer research,” said Linda Anderson, executive director, VCS. “VCS has participated in numerous early and late stage therapeutic trials over the last decade, many of which have developed into FDA-approved cancer therapies. Our researchers have also been part of dozens of publications related to their work. Joining the Multiple Myeloma Research Consortium adds to that commitment.”
Before being chosen as a MMRC member institution, Virginia Cancer Specialists went through a rigorous evaluation and was chosen based on both its extensive experience in conducting clinical trials and its impressive reach to the patient community.
“In addition to their expertise in working with patients in clinical trials, Virginia Cancer Specialists brings a true community practice to the Consortium,” said Kathy Giusti, Founder and CEO of the MMRC. “I look forward to them working in partnership with our elite membership to bring patients new treatments they urgently need.”
“Myeloma is a rare disease that we are dedicated to fighting,” said Alex I. Spira, M.D., director of research for VCS. “Our physicians and staff look forward to offering our patients more trials specifically targeting myeloma.”
Virginia Cancer Specialists serves the communities in the Northern Virginia area with nine locations located in Alexandria, Arlington (two locations), Fair Oaks, Fairfax, Gainesville, Loudoun, Winchester and Woodbridge.VCS offers a full range of oncology and hematology services, including clinical research and the use of evidence-based medicine and proactive patient support services. These provide patients with the best opportunity for a positive outcome and help to provide an overall better patient experience.
About Virginia Cancer Specialists
For more than 30 years, Virginia Cancer Specialists (VCS) has contributed to the campaign against cancer and diseases of the blood. VCS has nine locations throughout Northern Virginiastaffed by highly-skilled physicians, each promising exceptional care. This care consists of advancements in early detection, treatment, and clinical trials. Offering emotional as well as physical support, VCS is home to the world’s most advanced cancer treatment capabilities. By illustrating the outpatient emphasis of cancer treatment, VCS allows physicians and patients to create an individual plan in a familiar setting.
About the Multiple Myeloma Research Consortium
The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University. The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is an affiliate organization of the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in today's most promising research areas–genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit: www.themmrc.org.
Media Contact:
Natalie Mellon
Virginia Cancer Specialists
(703) 638-8619
# # #
Welcome to Dr. Jacob A. Ninan
On December 1st, Virginia Cancer Specialists will be welcoming a new medical oncologist. Dr. Jacob A. Ninan will be joining the Alexandria Office.
A 2002 graduate of the University of Michigan Medical School, Dr. Jacob Ninan went on to graduate from the University of Wisconsin's internal medicine residency program. After residency, he spent on year as the primary care chief medical resident at the William S. Middleton Memorial Veterans Hospital in Madison, Wisconsin. Dr. Ninan completed his hematology fellowship at the University of Wisconsin Carbone Comprehensive Cancer Center in 2008 and his oncology fellowship in 2010.
Dr. Ninan has previously done research in bone marrow transplantation and early phase clinical trials. He also has a special interest in hematologic malignancies as well as GI cancers.
A member of the American Society of Hematologists and the American Society of Clinical Oncologists, Dr. Ninan is also interested in international health and has done field work with Operation Crossroads in southern Africa. In his free time, he enjoys cycling, tennis, film, music and photography.
Please help us welcome Dr. Ninan to our Virginia Cancer Specialists family!
Washingtonian Magazine Features Breast Cancer Specialists
The October edition of the Washingtonian featured 66 Breast Cancer Specialists. This group of medical oncologists, radiation oncologists, breast cancer surgeons and plastic surgeons comes "highly recommended" and features Drs. Maran and Robert.
Congratulations to Dr. Maran and Robert and everyone else who contribute to improving the life of breast cancer patients!
Introducing Virginia Cancer Specialists
FairfaxNorthern Virginia Hematology Oncology Changes Its Name to Virginia Cancer Specialists
Name change represents growth and advancement of an already stellar and highly regarded cancer care practice
Fairfax, Va. (Sept. 27, 2010) — Fairfax Northern Virginia Hematology Oncology, P.C. (FNVHO), a 30-physician practice that has contributed to the campaign against cancer and diseases of the blood for more than three decades, has announced that it has changed its name to Virginia Cancer Specialists, P.C. (VCS). VCS is an affiliate of the United Network of US Oncology, the nation’s largest network of community-based oncologists dedicated to advancing cancer care and improving the cancer patient experience.
“The new name more accurately reflects who we are with expanded service from Arlington to Winchester and puts a stronger emphasis on our quality patient care,” said Linda Anderson, executive director, VCS. “The name Virginia Cancer Specialists is an outward sign that we are seeing tremendous enhancement in the quality of care and customer service for our patients as well as growth in our research program and clinical trials.”
Virginia Cancer Specialists offers a full range of oncology and hematology services, including clinical research and the use of evidence-based medicine and proactive patient support services. These provide patients with the best opportunity for a positive outcome and help to provide an overall better patient experience. As part of the US Oncology Research Network, Virginia Cancer Specialists participates in innovative clinical trials. The network has also played a role in the development of 42 cancer therapies approved by the Food and Drug Administration (FDA). In only three and a half years, patients enrolled in clinical trials at VCS more than doubled, and this number is continuing to grow.
“In 2007, we enrolled 74 cancer patients into clinical trials,” said Anderson. “We aren’t even in the fourth quarter of 2010, and we’ve already enrolled 166 patients. To add to that, VCS is the only site in Northern Virginia to offer the new drug Provenge, the first vaccine and latest immunotherapy for the treatment of prostate cancer. This is a huge testament of our commitment to bring cutting-edge research to our community.”
Virginia Cancer Specialists serves the communities in the Northern Virginia area with nine locations located in Alexandria, Arlington (two locations), Fair Oaks, Fairfax, Gainesville, Loudoun, Winchester and Woodbridge.
“The main focus of physicians and staff at Virginia Cancer Specialists is caring for our patients in the best way possible,” said Dr. Arthur Kales, practice president, VCS. “The name change represents a renewed commitment to improving cancer care and the overall patient experience. We don’t want to only treat the cancer; we want to care for the whole patient, emotionally and physically. That’s why we’ve launched the VCS new World Class Customer Service initiative that focuses on our new patient services campaign, A New Way of Caring.
Virginia Cancer Specialists has always had a stellar reputation for high quality cancer care and now has a new vision to take patient satisfaction to a higher level. Everything from improved signage around the office to fine tuning plans for a new patient portal that will give patients greater access to their medical team and records, A New Way of Caring emphasizes that at Virginia Cancer Specialists, the patient comes first.
“We are extremely excited about our new initiative and where VCS is headed,” said Dr. Kales. “Caring for patients is our specialty, and we are always looking for ways to enhance that care.”
The VCS new World Class Customer Service initiative will improve practice processes to be more convenient and accommodating for their patients both clinically and administratively. In line with the US Oncology Practice Quality and Efficiency (PQE) model, VCS is enhancing the patient experience. The PQE model, developed by US Oncology, uses elements of Lean Six Sigma to increase office efficiencies, mobilize change and make overall customer service improvements that result in better patient care - including shorter patient wait times and easy appointment scheduling.
Virginia Cancer Specialists is United in Healing with US Oncology. Patients treated through VCS have access to US Oncology’s vast patient services including clinical trials matching, Patient Assistance Support to help qualified patients gain access to financial assistance, proactive patient support calls from trained nurses who check on patients between physician visits, use of the Cancer Treatment Tool on the VCS website, access to the tools and resources of CUREMagazine, and the comfort of knowing their physician is part of a nationwide network of physicians who collaborate on tough cases to bring the best care to patients in their own hometown.
“Our new patient initiatives combined with US Oncology’s patient services and our shared commitment to personalized and evidence-based medicine will catapult the cancer care Virginia Cancer Specialists gives to patients to a higher level than ever before,” said Kales. “Caring for patients is our passion. We are excited to improve our service at VCS and provide our patients and their families with a better experience.”
About Virginia Cancer Specialists
For more than 30 years, Virginia Cancer Specialists (VCS) has contributed to the campaign againstcancer and diseases of the blood. VCS has nine locations throughout Northern Virginiastaffed by highly-skilled physicians, each promising exceptional care. This care consists ofadvancements in early detection, treatment, and clinical trials. Offering emotional as well asphysical support, VCS is home to the world’s most advanced cancer treatment capabilities. Byillustrating the outpatient emphasis of cancer treatment, VCS allows physicians and patients tocreate an individual plan in a familiar setting.
Virginia Cancer Specialists is United in Healing with US Oncology, Inc., the leading integrated oncology company. US Oncology unites the nation’s largest community-based cancer treatment and research network to expand patient access to high-quality care and advance the science of cancer care. As a member of the United Network of US Oncology, physicians and clinicians at Virginia Cancer Specialistsare united with more than 1,000 physicians and 10,000 cancer professionals from across the country. Through its affiliation with US Oncology and the US Oncology Research network, Virginia Cancer Specialists participates in innovative clinical trials. The network has also played a role in the development of 42 cancer therapies approved by the Food and Drug Administration (FDA). For more information, visit www.usoncology.com or www.virginiacancerspecialists.com.
Media Contacts:
Natalie Mellon Claire Crye
Virginia Cancer Specialists US Oncology
(703) 638-8619 (281) 863-6783
Natalie.Mellon@usoncology.com Claire.Crye@usoncology.com
# # #
Virginia Cancer Specialists Study Measuring Effects of Chemotherapy Dosing Schedule Published in Journal of Oncology Practice
Fairfax, VA, October 19, 2009 - Data from a study published in the November 2009 Journal of Oncology Practice details Fairfax Northern Virginia Hematology Oncology’s (FNVHO) initiative to put a quantitative value on quality by measuring the incidence and causes of substandard relative dose-intensity (RDI) among its patients with early stage breast cancer (ESBC).
RDI compares the actual dose and schedule of chemotherapy delivered to the intended dose and schedule of the standard chemotherapy regimen. While most metrics do not have a direct proven correlation with improvement in survival, measuring RDI does. Although controversial, the relationship between dose intensity of chemotherapy and patient outcomes is well documented in literature, and several studies discuss the significance of achieving more than 85 percent RDI. This data shows that failure to maintain 85percent, the patient’s survival rate is similar to those who never received chemotherapy.
Evidence continues to confirm that maintaining dose intensity for certain types of cancer increases disease-free survival and overall survival rates when the RDI is greater than 85%. The recent study published showed FNVHO with an RDI of 98.4 percent. “Prior to this initiative, RDI was not routinely calculated for our ESBC patients,” says Robert Bretzel, a lead author of the study. “However, since decreased RDI has been shown to correlate with decreased overall survival and disease-free survival, we were compelled to measure and determine the causative factors.”
Using a practice-wide electronic medical record (EMR), FNVHO retrospectively evaluated its experience of 834 patients in its large community-practice setting. For the purpose of this study, FNVHO focused on the subset group that showed a reduction in RDI. The practice reviewed data from eight of its treatment sites to determine trends by site. FNVHO also measured the average RDI in this subset by physician to determine trends.
Among its findings, the study showed:
- The average weighted RDI for all patients was 98.4 percent;
- Of the 834 evaluable patients FNVHO reviewed, 102 patients (12.2 percent) had some reduction in RDI. This subset had an average RDI of 88 percent; and
- Twenty-nine patients (3.5 percent) had a RDI of less than 85 percent.
The most common reasons FNVHO noted for dose delay were:
- Scheduling (both patient and medical reasons);
- Neutropenia (an abnormally low number of a type of white blood cells called neutrophils);
- Treatment toxicity; and
- Infection.
Sixty-five percent of scheduling delays were due to patient decision as opposed to office decision.
FNVHO also studied the cause of delays due to risk factors. Sixty percent of patients had no risk factors other than being female. Chronic disease and low hemoglobin were also noted as causes of dose delays.
Of the patients that were treated within the data range, FNVHO used its EMR to determine which subset of these patients experienced dose delays and/or dose reductions during their adjuvant (precautionary treatment given after surgery) chemotherapy treatments by reviewing individual charts. The data from the subset of patients with reduced dose delays/dose reductions were then entered into a RDI calculator, a software program written and supported by NearSpace.
“As part of a new quality initiative, we are translating this to other cancer types and will continue to measure RDI so that we can optimize patient outcomes, prevent recurrent disease, and understand the factors that cause reductions to RDI in our community-based practice,” says Dr. Anne Favret, an oncologist at FNVHO.
About FNVHO
Fairfax Northern Virginia Hematology Oncology (FNVHO) is northern Virginia’s premier oncology and hematology practice of board certified physicians. The practice has 33 physician experts on cancer, blood disorders and stem-cell transplantation in seven locations across northern Virginia. Comprehensive practice services include collaborative nursing, financial counseling and access to cutting-edge clinical trials through affiliations with US Oncology, the National Cancer Institute and many other cooperative groups. For more information, visit www.fnvho.com.
Virginia Cancer Specialists Participates in Personalized Clinical Trial for Colorectal Cancer
FAIRFAX, Va. – Imagine if treatments for disease could be based not on a patient’s diagnosis but instead on the characteristics of their tissue. By identifying and decoding the cryptic messages hidden deep inside the human proteome, scientists and physicians who study personalized medicine are seeking more effective treatments and disease management for patients.
Lance Liotta, MD, and Emanuel Petricoin, III, professors of life sciences and co-directors of George MasonUniversity’s Center for Applied Proteomics and Molecular Medicine (CAPMM), are pioneers in the field of patient-tailored research and personalized medicine. The two are studying biomarkers (or indicators of disease in tissue and bodily fluids) related to cancer, heart disease, liver disease and obesity.
They recently launched a unique clinical trial in partnership with oncologists and co-principal investigators Kirstin Edmiston, MD, medical director of cancer services at Inova Health System, and Alexander I. Spira, MD, director of Fairfax Northern Virginia Hematology Oncology Research Program, to treat patients with late-stage colorectal cancer, a fatal cancer that starts in either the colon or the rectum.
The three-year trial will accommodate up to 50 men and women who have late-stage colorectal cancer that has spread to the liver. Striking more than 150,000 men and women each year in the United States, colorectal cancer is the nation’s third most commonly diagnosed cancer and third leading cause of cancer death according to the American Cancer Society.
“Traditionally, all colon cancers have been lumped together and given similar treatments. The novelty about this is that we can, in a very minimally invasive way, start to treat the metastatic tumor based on its unique protein makeup. If we’re going to be successful in treating the metastatic disease, which is what kills people, then we need to focus on using therapies targeted towards the individuality of a patient’s disease state. This clinical trial is the first step toward doing that,” says Edmiston.
Trial participants will be treated with standard metastatic colon cancer therapy and will test the addition of Gleevec, a medicine that is typically prescribed for certain forms of leukemia and gastrointestinal tumors. Gleevec targets disease pathways in tumor cells that previous CAPMM research revealed were among those found in typically fatal liver metastasis in colorectal cancer patients.
Because the primary tumors in the colon are removed in most colorectal cancer patients as soon as they are diagnosed, this study will focus on treating the often fatal secondary tumors or metastatic lesions that appear when the disease spreads to the liver, causing death through destruction of that organ.
Using a new drug target mapping technology called “reverse phase protein microarray” that was developed by CAPMM’s scientists, the researchers will sample these lesions and create a unique molecular profile or “fingerprint” that shows which protein pathways or drug targets are activated in the lesion. This process will allow the researchers to determine whether specific drugs such as Gleevec might be an effective treatment for this particular patient before it is even administered.
By monitoring the drug target activity in trial participants’ tumors and basing their treatment on those characteristics, the researchers are hopeful that this clinical trial will lead to more effective and individualized treatment for patients who suffer from this devastating disease.
“The exciting aspect of this trial is that an established drug is being considered for a new indication, and that’s one of the promises of personalized therapy -- that a patient’s molecular portrait would be considered as the rationale for choice of therapy rather than based on the site or the kind of cancer alone,” says Petricoin. “Until now, the most cutting edge clinical trials utilize genomic profiling of the tumor to select patients. This is the first trial that uses a direct proteomic approach that maps the drug target activation networks that are in use in each patients’ tumor-- just technologically being able to do this in a real clinical trial is a first.”
Patients who are interested in participating should contact Stacey Banks, Inova’s clinical research coordinator at 703-776-3565.
Financial support for the study is being provided by Novartis, which developed and manufactures Gleevec.
About Inova Health System
Inova Health System is a not-for-profit healthcare system based in Northern Virginia that consists of hospital and other health services, including emergency- and unrgent-care centers, home care, nursing homes, mental health and blood donor services, and wellness classes. Governed by a voluntary board of community members, Inova's mission is to improve the health of the diverse community it serves through excellence in patient care, education and research. Inova provides a healthy environment for its patients, families, visitors, staff and physicians by prohibiting tobacco use on its campuses.
About Fairfax Northern Virginia Hematology Oncology
Fairfax Northern Virginia Hematology Oncology (FNVHO) is northern Virginia's premier oncology and hematology practice of board certified physicians. The practice has 33 physician experts on cancer, blood disorders and stem cell transplantation in seven locations across northern Virginia. Comprehensive practice services include collaborative nursing, financial counseling and access to cutting-edge clinical trials through affiliations with US Oncology, the National Cancer Institute and many other cooperative groups. For more information, visit www.fnvho.com.
About George Mason University
Named the #1 national university to watch in the 2009 rankings of U.S. News & World Report, GeorgeMason University is an innovative, entrepreneurial institution with global distinction in a range of academic fields. Located in Northern Virginia near Washington, D.C., Mason provides students access to diverse cultural experiences and the most sought-after internships and employers in the country. Mason offers strong undergraduate and graduate degree programs in engineering and information technology, organizational psychology, health care and visual and performing arts. With Mason professors conducting groundbreaking research in areas such as climate change, public policy and the biosciences, GeorgeMason University is a leading example of the modern, public university.
Washingtonian Magazine Names Top Docs
(Fairfax, Va.) - Fairfax Northern Virginia Hematology Oncology (FNVHO) is proud to announce the recognition of 17 of their medical oncologists by Washingtonian Magazine as Top Doctors 2010. The physicians included are:
Roy A. Beveridge, M.D. - Thomas P. Butler, M.D. - David M. Dunning, M.D. - John M. Feigert, M.D. - Arthur N Kales, M.D. - Daniel Katcher, M.D. - Alisan G. Kula, M.D. - Jey A. Maran, M.D. - Robert Marsh, M.D. - Robert Meister, M.D. - Gregory J. Orloff, M.D. - Dipti Patel-Donnelly, M.D. - Robert L. Reid, M.D. - Nicholas J. Robert, M.D. - Patricia A. Rodriguez, M.D. - Alex I. Spira, M.D. - Winston M. Ueno, M.D.
Washingtonian Magazine sent questionnaires to Washington, DC area physicians asking them what doctors they would send members of their families to in 34 medical specialties. “The “Top Doctors” in some respects constitute an all-star list,” said Linda Anderson, Executive Director of FNVHO. “We are very pleased, but not surprised that many of our physicians were listed among the “Top Doctors” for 2010.” To see a complete listing of Top Doctors, visit www.washingtonian.com.
About FNVHO
Fairfax Northern Virginia Hematology Oncology (FNVHO) is northern Virginia’s premier oncology and hematology practice of board certified physicians. The practice has 30 physician experts on cancer, blood disorders and stem-cell transplantation in seven locations across northern Virginia. Comprehensive practice services include collaborative nursing, financial counseling and access to cutting-edge clinical trials through affiliations with US Oncology, the National Cancer Institute and many other cooperative groups. For more information, visit www.fnvho.com.